Genes2Me announced today the launch of its wide range of Next-generation sequencing (NGS)-based panels for Oncology, Personalized Medicine and Hereditary Diseases. By selectively targeting the clinically significant genes, the NGS panels from Genes2Me enable comprehensive analysis with the most effective sequencing throughput. These panels have